Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.49 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27358581 | 1.00 | CYP1A2 (0.52) | CYP1A2CD274PDCD1SPHK1KDM4E | |
| SCHEMBL1818678 | 1.00 | CYP1A2 (0.52) | CYP1A2CD274PDCD1SPHK1KDM4E | |
| SCHEMBL31457101 | 0.88 | SPHK1 (0.60) | CD274PDCD1SPHK1KDM4ESMN1; SMN2 | |
| SCHEMBL27630427 | 0.86 | SMN1; SMN2 (0.46) | SPHK1KDM4ESMN1; SMN2TDP1MBTD1 | |
| SCHEMBL27358578 | 0.85 | ALDH1A1 (0.52) | SPHK1KDM4ESMN1; SMN2TDP1MEN1 | |
| SCHEMBL1972076 | 0.84 | CYP1A2 (0.60) | CYP1A2CD274PDCD1SPHK1SMN1; SMN2 | |
| SCHEMBL1819248 | 0.84 | CYP1A2 (0.60) | CYP1A2CD274PDCD1SPHK1SMN1; SMN2 | |
| SCHEMBL2587055 | 0.84 | CYP1A2 (0.60) | CYP1A2CD274PDCD1SPHK1SMN1; SMN2 | |
| SCHEMBL1815987 | 0.84 | NPBWR1 (0.53) | CYP1A2CD274PDCD1SPHK1KDM4E | |
| SCHEMBL3148367 | 0.84 | NPBWR1 (0.53) | CYP1A2CD274PDCD1SPHK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2022-03-24 | — | — | US | disclosed |
| US-10174077-B2 | Method of inhibiting activity of cell surface fibroblast activation protein alpha | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2019-01-08 | — | — | US | disclosed |
| US-10155789-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2018-12-18 | — | — | US | disclosed |
| US-20170260231-A1 | Substrates and Inhibitors of Prolyl Oligopeptidase and Methods of Use Thereof | UNIV OKLAHOMA (US) | 2017-09-14 | — | — | US | disclosed |
| US-9688722-B2 | Substrates and inhibitors of prolyl oligopeptidase and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170066800-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | UNIV OKLAHOMA (US) | 2017-03-09 | — | — | US | disclosed |
| US-9527884-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150141660-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| US-20150119330-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2015-04-30 | — | — | US | disclosed |
| EP-2844246-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | The Board of Regents of the University of Oklahoma (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8933201-B2 | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2015-01-13 | — | — | US | disclosed |
| WO-2013166438-A1 | SUBSTRATES AND INHIBITORS OF PROLYL OLIGOPEPTIDASE AND FIBROBLAST ACTIVATION PROTEIN AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20110144037-A1 | Substrates and Inhibitors of Antiplasmin Cleaving Enzyme and Fibroblast Activation Protein and Methods of Use | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2011-06-16 | — | — | US | disclosed |
| CN-101512338-A | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use thereof | MCKEE PATRICK A (US) | 2009-08-19 | — | — | CN | disclosed |
| EP-2038653-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | McKee, Patrick A. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220087971-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | CYP1A2 2416/4885CD274 2533/4885PDCD1 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.